Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
HER-2/neu oncoprotein is overexpressed in a variety of human tumors and is associated with malignant transformation and aggressive disease. Due to its overexpression in tumor cells and because it has been shown to be immunogenic, this protein represents an excellent target for T-cell immunotherapy. Peptide extracts derived from primary HLA-A*0201-positive (+) HER-2/neu+ human tumors by acid elution (acid cell extracts (ACEs)) were tested for their capacity to elicit in HLA-A*0201 transgenic mice, cytotoxic T lymphocytes (CTLs) lysing HLA-A*0201+ HER-2/neu+ tumor cells. Injections of ACE in transgenic mice induced CTLs capable of specifically lysing HER-2/neu+ tumor cell lines (also including the original HER-2/neu+ primary tumor cells from which the ACEs were derived) in an HLA-A*0201-restricted fashion. Adoptive transfer of ACE-induced CTLs was sufficient to significantly prolong survival of SCID mice inoculated with HLA-A*0201+ HER-2/ neu+ human tumor cell lines. Cytotoxicity of such ACE-induced CTL lines was directed, at least as detected herein, also against the HER-2/ neu peptides HER-2 (9(369)) and HER-2 (9(435)) demonstrating the immunodominance of these epitopes. HER-2 peptide-specific CTLs generated in the HLA-A*0201-transgenic mice, upon peptide immunization, lysed in vitro HER-2/neu+ human tumor cell lines in an HLA-A*0201-restricted manner and, when adoptively transferred, conferred sufficient protection in SCID mice inoculated with the same human tumor cell lines as above. However, CTLs induced by ACEs displayed enhanced efficacy in the therapy of xenografted SCID mice compared with the HER-2 peptide-specific CTLs (i.e., HER-2 [9(369)] or HER-2 [9(435)]). Even by administering mixtures of CTLs specific for each of these peptides, the prolongation of survival achieved was still inferior compared with that obtained with ACE-induced CTLs. This suggested that additional epitopes may contribute to the immunogenicity of such tumor-derived ACEs. Thus, immunization with ACEs from HER-2/neu+ primary tumor cells appears to be an effective approach to generate multiple and potent CTL-mediated immune responses against HER-2/neu+ tumors expressing the appropriate HLA allele(s). By screening ACE-induced CTL lines with synthetic peptides encompassing the HER-2/neu sequence, it is feasible to identify immunodominant epitopes which may be used in mixtures as vaccines with enhanced efficacy in both the prevention and therapy of HER-2/neu+ malignancies.
Gritzapis
Angelos D
AD
Cancer Immunology and Immunotherapy Center, Saint Savas Hospital, 171 Alexandras Avenue, 11522, Athens, Greece.
Sotiriadou
Nectaria N
NN
Papamichail
Michael
M
Baxevanis
Constantin N
CN
D000818:Animals; D000951:Antigens, Neoplasm / Q000737:chemistry; D017209:Apoptosis; D001943:Breast Neoplasms / Q000276:immunology* / Q000378:metabolism; D045744:Cell Line, Tumor; D000939:Epitopes; D005260:Female; D015789:HLA-A2 Antigen / Q000235:genetics*; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D016513:Mice, SCID; D008822:Mice, Transgenic; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000378:metabolism; D010455:Peptides / Q000737:chemistry; D013154:Spleen / Q000166:cytology; D013602:T-Lymphocytes, Cytotoxic / Q000737:chemistry / Q000276:immunology*; D013997:Time Factors; D014162:Transfection
D000951:Antigens, Neoplasm; D000939:Epitopes; D015789:HLA-A2 Antigen; D010455:Peptides